← Leaderboards
Frank Schoenen
University Of Kansas Medical Center
$1,243,019
Attributed
$3,729,056
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2017–22$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$3,729,056 · 2
By mechanism
R01$3,729,056 · 2
Top collaborators
- Anuradha Roy7 shared
- Michal Zolkiewski4 shared
- Andrew K Godwin3 shared
Most similar at University Of Kansas Medical Center
Same institution · by research overlap
- K Allen Greiner$16,416,087
- Jennifer Rose Klemp$2,052,231
- Elizabeth Ann Calhoun$12,119,635
- Liang Tang$2,136,669
- Edward F Ellerbeck$14,967,515
Others in their field
Other Emerging Leaders on “Drug Discovery”
- Leonard Freedman · Leidos Biomedical Research, Inc.$255,277,443
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$157,315,120
- Lynn Briscoe · Leidos Biomedical Research, Inc.$93,294,869
- John Damon Chodera · Sloan-Kettering Inst Can Research$64,994,606
- Leonard Freedmand · Leidos Biomedical Research, Inc.$52,916,621
- Gary Kobinger · University Of Texas Med Br Galveston$41,631,815
Research focus
Drug DiscoveryBaseStructureSmall Molecule InhibitorCytotoxicityCellsGrowthIn VitroMolecularPublic HealthProteinsNovel StrategiesBindingBiologyClinically RelevantInhibitor/AntagonistBiological TestingAssay DevelopmentBiological Adaptation To StressAntibiotic ResistanceDrug ResistanceDysenteryAntimicrobial DrugCombat
Grant awards (7)
Discovery of Hsp100-selective inhibitors for targeting multiple microbial pathogens$328,714
R01 · FY2022 · AI
Discovery of Hsp100-selective inhibitors for targeting multiple microbial pathogens$479,141
R01 · FY2021 · AI
Discovery of Hsp100-selective inhibitors for targeting multiple microbial pathogens$589,070
R01 · FY2020 · AI
Targeting Kinesin Family Member 15 for the Treatment of Cancer$553,464
R01 · FY2019 · CA
Discovery of Hsp100-selective inhibitors for targeting multiple microbial pathogens$514,035
R01 · FY2019 · AI
Targeting Kinesin Family Member 15 for the Treatment of Cancer$623,043
R01 · FY2018 · CA
Targeting Kinesin Family Member 15 for the Treatment of Cancer$641,589
R01 · FY2017 · CA